Introduction
============

Acute ischemic stroke (AIS) is one of the principal causes of disability and death, which causes great economic and mental burden to patients' families ([@ref-16]; [@ref-22]). Intravenous thrombolytic therapy and recombinant tissue plasminogen activator (rtPA) have been broadly used in AIS patients within 4.5 h after symptom onset ([@ref-25]).

Previous studies have shown that those who have hyperhomocysteinemia (Hhcy) have a higher risk of the development of AIS, and Hhcy is correlated with poor prognosis in AIS patients ([@ref-4]; [@ref-31]). Besides, the increased risk of cardiovascular disease could also be partially attributed to Hhcy ([@ref-1]). Its possible underlying mechanism is that elevated serum homocysteine (Hcy) may lead to endothelial dysfunction ([@ref-6]; [@ref-28]; [@ref-29]), neurotoxicity ([@ref-19]) and up-regulation of thrombosis formation factors ([@ref-5]; [@ref-9]). However, the likelihood of applying Hcy to prognosticate AIS patients' clinical outcomes after rtPA therapy hasn't been thoroughly investigated. Therefore, we designed this retrospective study to assess the potential relationship between clinical outcomes and Hcy in patients with AIS after rtPA therapy.

Materials and Methods
=====================

Patients
--------

The study was designed as a retrospective study. Patients with AIS taking rtPA treatment were enrolled between September 2018 and March 2019 in a single Stroke Center (Department of Neurology and Neurosurgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine). The study population included 205 consecutive patients admitted with AIS within 4.5 h of their symptom onset.

Exclusion criteria
------------------

Evidence of severe infection, cardiopulmonary disease, cancer, hepatic or renal disease, or multiple organ dysfunction. Patients with mental disorders, severe cognitive dysfunction, a history of mental problems and abnormal behavior were also excluded.

Data and design
---------------

The institutional ethics committee of Shanghai Tenth People's Hospital has approved this retrospective study. All investigations and methods were performed in accordance with Shanghai Tenth People's Hospital's guidelines and regulations. The consent form was not required due to the retrospective nature and de-identified nature of this retrospective study. The standard cardiological and neurological examinations were performed immediately on the patients' arrival in the emergency room. Before the initiation of therapy, the information about vital signs, blood chemistry and computed tomography scans was obtained. Information about previous and concomitant diseases were recorded. National Institutes of Health Stroke Scale (NIHSS) score was assessed ([@ref-2]). Adverse events of hemorrhage, including symptomatic intracerebral hemorrhage (sICH), were identified.

All patients underwent intravenous (i.v.) thrombolytic therapy using rtPA at a dose of 0.9 mg/kg. And those who were followed up for at least three months and had the available modified Rankin Scale (mRS) score ([@ref-26]) at three months from symptom onset were involved in the final retrospective analysis. Then we compared data about demographics, baseline and clinical characteristics between patients with favorable (mRS score 0--2) and unfavorable (mRS score 3--6) outcomes.

Statistical analysis
--------------------

Applying the Kolmogorov--Smirnov test to test if the metrological data followed the normal distribution or not. Mean ± standard deviation (SD) was used to express continuous variables that follow the normal distribution, and the median (quartiles) was used to indicate variables that do not follow a normal distribution. Frequencies or percentages were used to indicate categorical variables.

Chi-Square tests and Kruskal--Wallis *H* test or one-way ANOVA test were applied to detect any statistical difference between the means and proportions of the three groups.

Univariate analysis of baseline characteristics and clinical outcome were carried out. In this process, variables were added to the model with recoding into tertiles/binary or without recoding as needed.

Multiple logistic regression models were utilized to assess the association between serum Hcy levels and clinical outcome. Both non-adjusted and multivariate-adjusted models (variables adjusted for demographics (age, male)); hospital care factors (onset to treatment, door to needle time (DNT)); health and stroke factors (INR, D-Dimer, hemoglobin (HGB), NIHSS score before treatment, smoking, drinking, hypertension, diabetes, coronary disease, hyperlipidemia, previous stroke, atrial fibrillation, hemorrhagic transformation, internal carotid artery plaque) were applied. In this step, multivariate logistic regression models with the conditional forward selection method were used to reduce confounding factors' contribution and evaluate the independent contribution of Hcy to clinical outcome after adjusting different factors. All analyses were performed with the SPSS 22.0. A two-sided significance level of 0.05 was applied to assess statistical significance.

Results
=======

General patient characteristics
-------------------------------

Among 205 consecutive patients with AIS, 141 (68.78%) patients' follow-up data could be analyzed. Among them, 36 patients had poor outcomes, for an incidence of 25.53%. The data about baseline clinical findings, demographic characteristics and medical history records were summarized in [Table 1](#table-1){ref-type="table"}.
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###### Demographic data, baseline clinical findings, medical history and clinical outcome among patients with AIS receiving rtPA treatment.
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  Hcy tertile                               Bottom tertile *n* = 47   Middle tertile *n* = 47   Top tertile *n* = 47     *P*-value
  ----------------------------------------- ------------------------- ------------------------- ------------------------ -----------
  Age, year                                 64.00 (58.00--69.00)      67.00 (61.00--75.00)      67.00 (60.00--76.00)     0.136
  Male, *n* (%)                             25 (53.19)                34 (72.34)                34 (72.34)               0.078
  Onset to treatment, min                   150.00 (110.00--190.00)   154.00 (105.00--188.00)   126.00 (90.00--172.00)   0.103
  DNT, min                                  48.00 (39.00--57.00)      45.00 (40.00--57.00)      45.00 (35.00--53.00)     0.721
  INR                                       0.94 (0.92--1.00)         0.98 (0.94--1.05)         0.97 (0.95--1.02)        0.017
  D-Dimer, μg/mL                            0.38 (0.21--0.63)         0.68 (0.34--1.76)         0.57 (0.32--1.75)        0.008
  HGB, g/dL                                 5.90 (5.70--7.10)         6.10 (5.70--6.80)         6.10 (5.50--6.40)        0.572
  NIHSS score before treatment              5.00 (3.00--6.00)         5.00 (4.00--9.00)         7.00 (4.00--9.00)        0.060
  Hcy, μmol/L                               7.80 (7.00--9.00)         12.20 (10.90--13.00)      20.50 (16.40--26.10)     \<0.001
  Smoking, *n* (%)                          14 (29.79)                20 (42.55)                21 (44.68)               0.282
  Drinking, *n* (%)                         8 (17.02)                 9 (19.15)                 11 (23.40)               0.736
  Hypertension, *n* (%)                     33 (70.21)                38 (80.85)                38 (80.85)               0.369
  Diabetes, *n* (%)                         24 (51.06)                19 (40.43)                22 (46.81)               0.587
  Coronary disease, *n* (%)                 1 (2.13)                  4 (8.51)                  2 (4.26)                 0.354
  Hyperlipidemia, *n* (%)                   17 (36.17)                18 (38.30)                13 (27.66)               0.521
  Previous stroke, *n* (%)                  8 (17.02)                 7 (14.89)                 10 (21.28)               0.716
  Atrial fibrillation, *n* (%)              3 (6.38)                  11 (23.40)                8 (17.02)                0.072
  Hemorrhagic transformation, *n* (%)       3 (6.38)                  4 (8.51)                  3 (6.38)                 0.900
  Internal carotid artery plaque, *n* (%)   33 (70.21)                37 (78.72)                36 (76.60)               0.616
  mRS at 3 month, *n* (%)                                                                                                0.096
  \<3                                       39 (82.98)                36 (76.60)                30 (63.83)               
  \>=3                                      8 (17.02)                 11 (23.40)                17 (36.17)               

**Notes:**

*P* value calculated from Kruskal--Wallis *H* test and Chi-Square tests were used to determine any statistical difference between the means and proportions of the three groups.

AIS, acute ischemic stroke; rtPA, recombinant tissue plasminogen activator; Hcy, homocysteine; DNT, door to needle time; INR, international standard ratio; HGB, hemoglobin; NIHSS, national institutes of health stroke scale; mRS, modified rankin scale.

Univariate logistic regression analysis
---------------------------------------

[Table 2](#table-2){ref-type="table"} presents the association between outcomes at 90 days and each baseline characteristic. Consistent with the available literature, higher Hcy levels (OR = 1.07, 95% CI \[1.02--1.12\]), older age (OR = 1.06, 95% CI \[1.02--1.10\]), longer DNT (OR = 1.03, 95% CI \[1.01--1.05\]), higher D-Dimer levels (OR = 1.33, 95% CI \[1.03--1.71\]), and higher NIHSS score before treatment (OR = 1.21, 95% CI \[1.08--1.35\]) were each associated with poor outcome. Without internal carotid artery plaque (OR = 0.30, 95% CI \[0.10--0.92\]) showed a protective effect on patients' clinical outcome. The OR for poor outcomes was 0.36 (95% CI \[0.14--0.95\]), 0.24 (95% CI \[0.08--0.67\]), 0.24 (95% CI \[0.08--0.67\]), 0.09 (95% CI \[0.03--0.34\]) in individuals with Hcy levels, age, D-Dimer levels, NIHSS score before treatment in the bottom tertile compared with those in the top tertile ([Table 2](#table-2){ref-type="table"}).
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###### Univariate analysis of baseline characteristics and clinical outcome.
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  Exposure                               Statistics               Clinical outcome at 3 months   *P* value
  -------------------------------------- ------------------------ ------------------------------ -----------
  Hcy, μmol/L                            12.20 (9.00--16.45)      1.07 (1.02, 1.12)              0.006
  Hcy tertile                                                                                    
  Bottom tertile                         47 (33.33%)              0.36 (0.14, 0.95)              0.039
  Middle tertile                         47 (33.33%)              0.54 (0.22, 1.33)              0.18
  Top tertile                            47 (33.33%)              reference                      
  Gender                                                                                         
  Male                                   93 (65.96%)              1.04 (0.47, 2.33)              
  Female                                 48 (34.02%)              reference                      0.917
  Age, year                              66.00 (60.00--73.50)     1.06 (1.02, 1.10)              0.006
  Age tertile                                                                                    
  Bottom tertile                         47 (33.33%)              0.24 (0.08, 0.67)              0.006
  Middle tertile                         47 (33.33%)              0.55 (0.23, 1.33)              0.187
  Top tertile                            47 (33.33%)              reference                      
  Onset to treatment, min                139.00 (100.00--182.5)   1.00 (1.00, 1.01)              0.405
  Onset to treatment tertile                                                                     
  Bottom tertile                         47 (33.33%)              0.56 (0.21, 1.46)              0.233
  Middle tertile                         47 (33.33%)              0.90 (0.37, 2.20)              0.820
  Top tertile                            47 (33.33%)              reference                      
  DNT, min                               45.00 (37.50--55.00)     1.03 (1.01, 1.05)              0.013
  DNT tertile                                                                                    
  Bottom tertile                         47 (33.33%)              0.52 (0.21, 1.32)              0.170
  Middle tertile                         47 (33.33%)              0.52 (0.21, 1.32)              0.170
  Top tertile                            47 (33.33%)              reference                      
  INR                                    0.97 (0.93--1.02)        11.61 (0.32, 416.15)           0.179
  INR tertile                                                                                    
  Bottom tertile                         47 (33.33%)              0.71 (0.27, 1.82)              0.473
  Middle tertile                         47 (33.33%)              1.00 (0.41, 2.47)              1.000
  Top tertile                            47 (33.33%)              reference                      0.433
  D-Dimer, μg/mL                         0.54 (0.31--1.21)        1.33 (1.03, 1.71)              0.027
  D-Dimer tertile                                                                                
  Bottom tertile                         48 (33.57%)              0.24 (0.08, 0.67)              0.006
  Middle tertile                         47 (32.87%)              0.55 (0.23, 1.33)              0.187
  Top tertile                            48 (33.57%)              reference                      
  Smoking                                                                                        
  Yes                                    55 (39.01%)              reference                      
  No                                     86 (60.99%)              1.64 (0.73, 3.68)              0.231
  Drinking                                                                                       
  Yes                                    28 (19.86%)              reference                      
  No                                     113 (80.14%)             1.33 (0.49, 3.58)              0.579
  Hypertension                                                                                   
  Yes                                    109 (77.30%)             reference                      
  No                                     32 (22.70%)              0.47 (0.17, 1.32)              0.150
  Diabetes                                                                                       
  Yes                                    65 (46.10%)              reference                      
  No                                     76 (53.90%)              0.70 (0.33, 1.49)              0.353
  Coronary disease                                                                               
  Yes                                    7 (4.96%)                reference                      
  No                                     134 (95.04%)             0.44 (0.09, 2.05)              0.293
  Hyperlipidemia                                                                                 
  Yes                                    48 (34.04%)              reference                      
  No                                     93 (65.96%)              1.77 (0.76, 4.16)              0.188
  Previous stroke                                                                                
  Yes                                    25 (17.73%)              reference                      
  No                                     116 (82.27%)             1.85 (0.74, 4.67)              0.190
  Atrial fibrillation                                                                            
  Yes                                    22 (15.60%)              reference                      
  No                                     122 (84.40%)             0.84 (0.28, 2.45)              0.743
  Hemorrhagic transformation                                                                     
  Yes                                    10 (7.09%)               reference                      
  No                                     131 (92.91%)             0.79 (0.19, 3.22)              0.737
  Internal carotid artery plaque                                                                 
  Yes                                    106 (75.18%)             reference                      
  No                                     105 (24.82%)             0.30 (0.10, 0.92)              0.034
  HGB, g/dL                              6.00 (5.65--6.85)        0.95 (0.75, 1.20)              0.639
  HGB tertile                                                                                    
  Bottom tertile                         45 (33.33%)              0.79 (0.30,2.06)               0.624
  Middle tertile                         45 (33.33%)              1.24 (0.50, 3.10)              0.642
  Top tertile                            45 (33.33%)              reference                      
  NIHSS score before treatment           5.00 (4.00--8.00)        1.21 (1.08, 1.35)              0.001
  NIHSS score before treatment tertile                                                           
  Bottom tertile                         47 (33.33%)              0.09 (0.03,0.34)               \<0.001
  Middle tertile                         47 (33.33%)              0.52 (0.22, 1.22)              0.133
  Top tertile                            47 (33.33%)              reference                      

**Note:**

AIS, acute ischemic stroke; Hcy, homocysteine; DNT, door to needle time; INR, international standard ratio; HGB, hemoglobin; NIHSS, national institutes of health stroke scale; mRS, modified rankin scale.

Subgroup analysis
-----------------

We further explored the role of other covariables on the association between Hcy levels and outcome. The impact of Hcy levels on outcome exhibited a significant difference in DNT subgroups (*P* = 0.037), whereas no difference in the following subgroups: age, gender, onset to treatment, INR, D-Dimer, smoking, drinking, hypertension, diabetes, coronary disease, hyperlipidemia, previous stroke, atrial fibrillation, hemorrhagic transformation, internal carotid artery plaque, HGB and NIHSS score before treatment (all *P* value for interaction is more than 0.05) ([Table 3](#table-3){ref-type="table"}).
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###### Subgroup analysis of Hcy levels with clinical outcome according to covariates by logistic regression.
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  Subgroup                               OR (95% CI)           *P* value   *P* value for interaction
  -------------------------------------- --------------------- ----------- ---------------------------
  Age tertile                                                              0.603
  Bottom tertile                         1.09 \[1.00--1.19\]   0.055       
  Middle tertile                         1.05 \[0.98--1.13\]   0.186       
  Top tertile                            1.06 \[0.97--1.15\]   0.239       
  Gender                                                                   0.385
  Male                                   1.06 \[1.01--1.12\]   0.024       
  Female                                 1.12 \[1.00--1.25\]   0.047       
  Onset to treatment tertile                                               0.381
  Bottom tertile                         1.07 \[0.98--1.17\]   0.120       
  Middle tertile                         1.01 \[0.93--1.10\]   0.812       
  Top tertile                            1.13 \[1.03--1.23\]   0.010       
  DNT tertile                                                              0.037
  Bottom tertile                         1.15 \[1.04--1.28\]   0.008       
  Middle tertile                         1.08 \[1.00--1.18\]   0.064       
  Top tertile                            1.00 \[0.92--1.09\]   0.923       
  INR Tertile                                                              0.485
  Bottom tertile                         1.09 \[0.99--1.21\]   0.070       
  Middle tertile                         1.07 \[1.00--1.14\]   0.052       
  Top tertile                            1.04 \[0.94--1.15\]   0.466       
  D-Dimer tertile                                                          0.124
  Bottom tertile                         1.18 \[1.02--1.37\]   0.030       
  Middle tertile                         1.05 \[0.98--1.12\]   0.204       
  Top tertile                            1.03 \[0.94--1.13\]   0.585       
  Smoking                                                                  0.713
  Yes                                    1.09 \[1.00--1.18\]   0.048       
  No                                     1.07 \[1.00--1.13\]   0.035       
  Drinking                                                                 0.807
  Yes                                    1.08 \[0.96--1.23\]   0.196       
  No                                     1.07 \[1.01--1.12\]   0.013       
  Hypertension                                                             0.282
  Yes                                    1.05 \[0.99--1.10\]   0.101       
  No                                     1.16 \[0.97--1.38\]   0.105       
  Diabetes                                                                 0.066
  Yes                                    1.13 \[1.04--1.23\]   0.004       
  No                                     1.03 \[0.98--1.09\]   0.212       
  Coronary disease                                                         0.937
  Yes                                    1.08 \[0.81--1.44\]   0.595       
  No                                     1.07 \[1.02--1.12\]   0.007       
  Hyperlipidemia                                                           0.886
  Yes                                    1.07 \[0.96--1.20\]   0.218       
  No                                     1.06 \[1.01--1.12\]   0.020       
  Previous stroke                                                          0.556
  Yes                                    1.04 \[0.95--1.14\]   0.368       
  No                                     1.08 \[1.02--1.14\]   0.011       
  Atrial fibrillation                                                      0.608
  Yes                                    1.11 \[0.95--1.30\]   0.188       
  No                                     1.06 \[1.01--1.12\]   0.012       
  Hemorrhagic transformation                                               0.612
  Yes                                    1.00 \[0.77--1.30\]   1.000       
  No                                     1.07 \[1.02--1.12\]   0.005       
  Internal carotid artery plaque                                           0.193
  Yes                                    1.06 \[1.01--1.12\]   0.019       
  No                                     1.07 \[0.98--1.16\]   0.133       
  HGB tertile                                                              0.506
  Bottom tertile                         1.07 \[0.99--1.16\]   0.085       
  Middle tertile                         1.05 \[0.98--1.11\]   0.146       
  Top tertile                            1.14\[1.01--1.28\]    0.032       
  NIHSS score before treatment tertile                                     0.791
  Bottom tertile                         0.83 \[0.60--1.16\]   0.275       
  Middle tertile                         1.21 \[1.06--1.38\]   0.005       
  Top tertile                            1.03 \[0.97--1.09\]   0.383       

**Note:**

Hcy, homocysteine; DNT, door to needle time; INR, international standard ratio; HGB, hemoglobin; NIHSS, national institutes of health stroke scale; mRS, modified rankin scale.

Multivariate logistic regression analysis
-----------------------------------------

Patients with higher levels of Hcy decline also show an elevated risk of poor outcome for AIS patients obtaining rtPA treatment (Non-adjusted: OR = 1.07, 95% CI \[1.02--1.12\]; Adjust model I adjusts for demographics (age, male): OR = 1.06, 95% CI \[1.02--1.11\]; Adjust model II adjusts for hospital care factors (onset to treatment, DNT): OR = 1.08, 95% CI \[1.03--1.13\]); Adjust model III adjusts for health and stroke factors (INR, D-Dimer, HGB, NIHSS score before treatment, smoking, drinking, hypertension, diabetes, coronary disease, hyperlipidemia, previous stroke, atrial fibrillation, hemorrhagic transformation, internal carotid artery plaque): OR = 1.06, 95% CI \[1.02--1.11\]. The results are very stable in all three models constructed ([Table 4](#table-4){ref-type="table"}).
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###### Odds ratios of Hcy levels for the clinical outcome by logistic regression.
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  --------------------------------------------------------------------------------------------------------------------------------------------------
  Exposure   Non-adjusted\         *P* value   Adjust Model I\       *P* value   Adjust Model II\      *P* value   Adjust Model II\      *P* value
             OR (95% CI)                       OR (95% CI)                       OR (95% CI)                       OR (95% CI)           
  ---------- --------------------- ----------- --------------------- ----------- --------------------- ----------- --------------------- -----------
  Hcy        1.07 \[1.02--1.12\]   0.006       1.06 \[1.02--1.11\]   0.006       1.08 \[1.03--1.13\]   0.003       1.06 \[1.02--1.11\]   0.009

  --------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

The non-adjusted model adjusts for none.

Adjust model I adjust for: demographics (age, male).

Adjust model II adjust for: hospital care factors (onset to treatment, DNT).

Adjust model III adjust for: health and stroke factors (INR, D-Dimer, HGB, NIHSS score before treatment, smoking, drinking, hypertension, diabetes, coronary disease, hyperlipidemia, previous stroke, atrial fibrillation, hemorrhagic transformation, internal carotid artery plaque).

Discussion
==========

Currently, intravenous thrombolysis (IVT) with alteplase is the standard treatment approved for AIS patients within 4.5 h of the onset of their symptoms ([@ref-25]). In this study, we found that high level of Hcy, as a predictor for poor prognosis at three months in AIS patients receiving rtPA therapy, has important clinical implications. We also demonstrated that the risk of poor prognosis in AIS patients taking IVT increased by approximately 10% for every 1 μmol/L increase in serum Hcy concentration.

In the past decade, an enormous amount of epidemiological evidence supports the correlation between high Hcy levels and increased risk of the development of AIS ([@ref-3]; [@ref-13]), and some researchers have discovered that increased serum Hcy levels are related to increased hematoma volume ([@ref-8]; [@ref-32]). Previous studies also demonstrated that increased Hcy levels are correlated with functional disability in the acute phase of stroke ([@ref-18]; [@ref-24]). A prospective multicenter research conducted by Kwon et al. unveiled that the risk of early neurological deterioration increased along with the increase of Hcy levels in patients with ischemic stroke ([@ref-10]). However, whether high Hcy levels can be regarded as an independent risk factor for unfavorable clinical outcome in ischemic stroke patients accepting IVT has not been well addressed. Though a small number of studies have already been published, the prognostic value of Hcy levels in patients with AIS after IVT remains controversial. Some investigations revealed that Hhcy was correlated with unfavorable outcomes in patients with ischemic stroke ([@ref-11]; [@ref-14]; [@ref-30]), whereas some other studies indicated that there was no significant correlation between Hhcy and ischemic stroke patients' clinical outcome ([@ref-20], [@ref-21]). To further confirm the association between Hcy levels and clinical outcome of AIS patients treated with thrombolytic therapy, we conducted this retrospective study. Consistent with the previous retrospective studies conducted by [@ref-11], [@ref-14] and [@ref-30], we found that there exists a correlation between Hcy levels and poor prognosis after acute thrombolytic therapy in AIS patients in this retrospective study. And we indicated that higher Hcy levels have a negative impact on prognosis. The result of our study implements new proof that Hhcy has a negative impact on ischemic stroke patients' clinical outcome.

The underlying mechanism may be due to impaired vascular wall integrity and disturbance of cerebrovascular permeability resulting from increased levels of Hcy, which may lead to endothelial dysfunction, damage to elastic structures and damage to the basal layer of cerebral arterioles and microvessels ([@ref-7]; [@ref-15]).

Some studies have consistently shown that hyperhomocysteinemia is an independent risk factor for atherosclerosis' development, suggesting that raised plasma levels of Hcy are relevant to endothelial dysfunction ([@ref-1]; [@ref-12]; [@ref-27]). Besides, high Hcy levels also increase low-density lipoproteins oxidation, and the dominant mechanism by which Hcy adversely affects vascular endothelial function involves oxidative stress and bioactive nitric oxide consumption ([@ref-17]; [@ref-23]).

Our research also has some restrictions. First, this study is a single-center retrospective study and the sample size is limited. Second, we did not include patients who did not receive thrombolytic therapy, thus may resulting in a selective bias. Third, the Hcy level could be affected by various factors, such as genetic factors and drugs. But we didn't evaluate the reason for Hhcy in this study cohort. Also, almost all ORs for Hcy are close to 1 in our results. The contribution of Hcy to the outcome, although significant, is relatively small and perhaps not clinically significant when considering all other confounders. Hence, the results should be explained with caution, and the results should be further confirmed in a multicenter prospective study with a larger cohort to clearly establish the correlation between Hhcy and unfavorable outcome in ischemic stroke patients accepting IVT.

Conclusions
===========

In conclusion, the results of this study indicate that increased Hcy level independently predicts unfavorable outcome in AIS patients accepting thrombolytic therapy. However, the contribution of Hcy to the outcome, although significant, is relatively small when all the other confounders are considered. To better guide clinical practice, the further multicenter prospective study still needs to be done to clearly clarify the correlation between Hcy level and clinical outcome of AIS patients treating with intravenous thrombolysis.
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